Aricept

Donepezil is a potent, reversible acetylcholinesterase inhibitor primarily indicated for the symptomatic treatment of mild, moderate, and severe Alzheimer's disease by enhancing cholinergic function.

The dosing of Donepezil is carefully structured to minimize side effects while maximizing therapeutic benefits. Treatment typically begins at a low dose and is gradually increased.

• Mild to Moderate Alzheimer's Disease: The standard starting dose is 5 mg taken once daily. Clinical guidelines suggest that patients should remain on the 5 mg dose for at least 4 to 6 weeks. This period allows the body to adjust to the medication and for steady-state blood levels to be achieved. If the 5 mg dose is well-tolerated, a healthcare provider may increase the dose to 10 mg once daily. While 10 mg is often more effective than 5 mg, it is also associated with a higher incidence of cholinergic side effects.
• Moderate to Severe Alzheimer's Disease: For patients who have been on a stable dose of 10 mg once daily for at least 3 months, a higher dose of 23 mg once daily may be considered. This high-dose formulation is specifically designed to provide additional cognitive support in advanced stages of the disease. However, the 23 mg dose significantly increases the risk of nausea and vomiting.

Donepezil is NOT approved for use in pediatric patients. The safety and efficacy of Donepezil in children and adolescents have not been established. Clinical trials in pediatric populations for conditions like ADHD or autism have generally not shown sufficient benefit to warrant approval, and the risk profile in developing brains is not fully understood.

Renal Impairment

Pharmacokinetic studies indicate that the clearance of Donepezil is not significantly altered by the degree of renal function. Therefore, no specific dosage adjustment is typically required for patients with kidney disease. However, these patients should still be monitored closely for general tolerability.

Hepatic Impairment

Since Donepezil is primarily metabolized by the liver, patients with mild to moderate hepatic impairment (Child-Pugh Class A or B) may experience slower clearance of the drug. While specific dose reduction formulas are not standardized, healthcare providers often exercise caution and may titrate the dose more slowly in these individuals. Data for severe hepatic impairment is lacking.

Elderly Patients

No specific dosage adjustments are required based solely on age. However, because elderly patients are more likely to have co-morbidities and take multiple medications, they should be monitored for bradycardia (slow heart rate) and weight loss, which are common concerns in this demographic.

• Timing: Donepezil is most commonly taken once daily in the evening, just before bedtime. This timing is often recommended to help the patient 'sleep through' the peak of gastrointestinal side effects like nausea.
• Administration: The standard tablets should be swallowed whole with a full glass of water. They should not be crushed or split, especially the 23 mg extended-release version, as this can alter the absorption rate and increase the risk of toxicity.
• ODT Formulation: If using the Orally Disintegrating Tablet, allow it to dissolve on the tongue and then follow with a drink of water. Do not attempt to swallow the ODT whole.
• Food: Donepezil can be taken with or without food. If stomach upset occurs, taking it with a light snack may be beneficial.
• Storage: Store the medication at room temperature (68°F to 77°F or 20°C to 25°C), away from moisture and direct light.

If a dose of Donepezil is missed, the patient should take it as soon as they remember. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Do not 'double up' or take two doses at once to make up for a missed one. If the medication is missed for 7 days or longer, consult a healthcare provider before restarting, as a slow re-titration from the 5 mg dose may be necessary to avoid severe side effects.

An overdose of Donepezil can lead to a 'cholinergic crisis,' which is a life-threatening condition. Symptoms include severe nausea, vomiting, salivation, sweating, bradycardia (slow heart rate), hypotension (low blood pressure), respiratory depression, muscle weakness, and convulsions.

In the event of a suspected overdose, emergency medical services should be contacted immediately. Tertiary anticholinergics such as atropine may be used as an antidote. The recommended initial dose of atropine IV is 1.0 to 2.0 mg, with subsequent doses based on clinical response.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking the medication without medical guidance, as symptoms of dementia may worsen upon discontinuation.

Because Donepezil increases the levels of acetylcholine throughout the body, not just in the brain, it can cause 'cholinergic' side effects in the digestive system and other organs. The most common side effects reported in clinical trials include:

• Nausea and Vomiting: These are the most frequent complaints, especially during the first few weeks of treatment or after a dose increase. Nausea usually feels like a general queasiness or 'seasickness.'
• Diarrhea: Increased cholinergic activity stimulates the muscles of the gastrointestinal tract, leading to loose stools or increased frequency of bowel movements.
• Insomnia: Some patients report difficulty falling or staying asleep. If this occurs, a doctor may suggest moving the dose from bedtime to the morning.
• Muscle Cramps: Patients may experience sudden, involuntary contractions of the muscles, often in the legs.

Donepezil is a powerful medication that affects the autonomic nervous system. It must be used with caution in patients with certain underlying medical conditions. Caregivers should be vigilant in monitoring the patient’s physical health, particularly during the initiation of therapy and following any dosage increases. The most critical safety concern is the drug's effect on the heart and the gastrointestinal system.

No FDA black box warnings for Donepezil. Unlike some antipsychotic medications used in dementia, Donepezil does not carry a boxed warning for increased mortality in elderly patients, though it must still be used judiciously.

• Cardiovascular Conditions: Donepezil has vagotonic effects on the sinoatrial and atrioventricular nodes of the heart. This can manifest as bradycardia (slow heart rate) or heart block in patients both with and without known underlying cardiac conduction abnormalities. Syncopal episodes (fainting) have been reported in association with Donepezil use. Patients with 'sick sinus syndrome' or other supraventricular cardiac conduction conditions are at particularly high risk.

While there are few absolute contraindications for drug combinations with Donepezil, certain drugs should be avoided due to direct pharmacological antagonism:

• Anticholinergic Agents: Drugs such as atropine, benztropine, or scopolamine work in the exact opposite way of Donepezil. Taking these together will neutralize the effects of both medications. This also includes older antihistamines (like diphenhydramine) and certain overactive bladder medications (like oxybutynin). Using these can lead to a 'prescribing cascade' where one drug is used to treat the side effects of another, ultimately worsening the patient's confusion.

• NSAIDs (Nonsteroidal Anti-inflammatory Drugs): Combining Donepezil with drugs like ibuprofen, naproxen, or high-dose aspirin significantly increases the risk of stomach ulcers and internal bleeding. This is because Donepezil increases stomach acid while NSAIDs weaken the stomach lining.

Donepezil must NEVER be used in the following circumstances:

• Known Hypersensitivity: Patients who have had a documented severe allergic reaction (anaphylaxis, severe rash, angioedema) to donepezil hydrochloride or to piperidine derivatives. Piperidine derivatives are a chemical class that includes certain other medications; a pharmacist can help identify these.
• Severe Allergic Reaction to Inactive Ingredients: Each tablet contains various fillers (like lactose or magnesium stearate). A known life-threatening allergy to any of these components is an absolute contraindication.

These are conditions where the risk of using Donepezil may outweigh the benefits, requiring a careful risk-benefit analysis by a medical specialist:

• Sick Sinus Syndrome or Conduction Defects

Donepezil is classified as FDA Pregnancy Category C (under the older system). This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. There is no clinical indication for Donepezil in pregnant women, as Alzheimer's disease is extremely rare in women of childbearing age. If a woman of childbearing potential is prescribed Donepezil for an off-label use, she should be informed of the potential risks, and the drug should only be used if the potential benefit justifies the potential risk to the fetus.

It is not known whether Donepezil is excreted in human breast milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Donepezil, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. In general, breastfeeding is not recommended while taking this medication.

Donepezil is not indicated for use in children. Clinical trials in children with various cognitive disorders have not demonstrated efficacy and have raised concerns about the impact of long-term cholinesterase inhibition on the developing nervous system. If a child accidentally ingests Donepezil, seek emergency medical attention immediately for potential cholinergic crisis.

Donepezil hydrochloride is a piperidine-based, reversible inhibitor of the enzyme acetylcholinesterase (AChE). Its primary molecular target is the catalytic site of AChE, the enzyme responsible for the hydrolysis of the neurotransmitter acetylcholine into choline and acetate. By forming a reversible complex with the enzyme, Donepezil prevents the breakdown of acetylcholine in the synaptic cleft. This results in an increased concentration of acetylcholine available for binding to nicotinic and muscarinic receptors. Donepezil is highly selective for AChE over butyrylcholinesterase (BChE), which is found more predominantly in the periphery; this selectivity is thought to minimize peripheral side effects compared to older inhibitors like tacrine.

The pharmacodynamic effect of Donepezil is the enhancement of cholinergic neurotransmission. The degree of AChE inhibition in red blood cells has been shown to correlate with the plasma concentration of the drug. At a dose of 5 mg/day, steady-state inhibition of AChE is approximately 63-67%, while at 10 mg/day, it increases to about 77-82%. The onset of action is gradual, with cognitive improvements typically becoming measurable after 3 to 6 weeks of consistent use. The duration of effect is long, consistent with its 70-hour half-life; it takes approximately 2 weeks for the drug to be fully cleared from the system and for enzyme activity to return to baseline after discontinuation.